YOYoshiaki Osaka

Yoshiaki Osaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yoshiaki Osaka has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 November 2017
      • Vol. 44  (12) , 1547-1549

    [A Case of T4 Esophageal Cancer with Refractory Chylothorax Developed Postoperatively].

    by Yoshihiro Ota, Shingo Tachibana, Kosuke Takahashi, Takafumi Watanabe, Takeshi Suda, Sumito Hoshino, Yoshiaki Osaka, Kazuhiko Kasuya, Kenji Katsumata, Akihiko Tsuchida

    A 65-year-old man was diagnosed as having middle thoracic esophageal cancer(c-T3N2M0, stage III ), and neoadjuvant chemoradiotherapy was performed.We performed surgical therapy.However, tumor and #113 lymph node invasion into the aortic arch was observed; therefore, it was judged that curative resection was difficult, and R2 surgery was performed instead. Postoperative diagnosis was Mt, CRT-type 5b, s-T4(aortic arch)N4(#113)M0, stage IV a.After surgery, pleural effusion was abundant and was diagnosed as chylothorax.Even though intestinal rest and octreotide administration were performed as a conservative treatment, chylothorax was not improved.Therefore, thoracoscopic thoracic duct ligation was performed on 8POD.After that, pleural effusion was still sustained, and pleural adhesions were performed.However, it did not prove to be effective.Furthermore, when Lipiodol lymphangiography was performed to identify the leakage site, the leakage of contrast medium was observed from the remaining lymph node.After lymphangiography twice(in total), pleural effusion disappeared, and the patient was discharged on the 75POD.In this case, we report an example in which lymph leakage disappeared due to lymphangiography for diagnostic purpose, while no improvement was observed in the lymphatic leakage from the remaining metastatic lymph node in T4 esophageal cancer with R2 surgery, nor with some treatments for chylothorax, including thoracic duct ligation.


    • 1 March 2016
      • Vol. 36  (3) , 987-94

    Phase I Study of Docetaxel, Cisplatin, and 5-Fluorouracil Chemoradiotherapy for Local or Metastatic Esophageal Cancer.

    by Kenichi Iwasaki, Yoshiaki Osaka, Shingo Tachibana, Takeshi Suda, Yoshihiro Ota, Sumito Hoshino, Akihiko Tsuchida

    Chemoradiotherapy outcomes for unresectable esophageal cancer remain poor. We designed a phase I study of docetaxel, cisplatin (CDDP), and 5-fluorouracil (5-FU) chemoradiotherapy. Patients with T4 or M1 esophageal squamous cell carcinoma were enrolled. They received 2 chemotherapy cycles every 4 weeks with these initial doses (Phase I): docetaxel and CDDP (50 mg/m(2), days 1 and 29) with continuous 5-FU infusion (600 mg/m(2)/day, days 1-5 and 29-33). Concurrent radiotherapy (60 Gy) was initiated on day 1. Docetaxel and CDDP plus 5-FU doses were increased to 60 mg/m(2) plus 800 mg/m(2)/day. Out of the 15 patients enrolled, 13 completed the treatment. The MTDs were as follows: docetaxel (60 mg/m(2)), CDDP (60 mg/m(2)), and 5-FU (800 mg/m(2)/day). The overall response rate was 73%, with 27% achieving complete responses. In this phase I trial, docetaxel (60 mg/m(2)), CDDP (60 mg/m(2)), and 5-FU (600 mg/m(2)/day) were considered as the tolerable and active doses. These are the recommended doses for a future phase II trial.

    • 1 March 2013
      • Vol. 33  (3) , 1157-61

    Tumor response after low-dose preoperative radiotherapy combined with chemotherapy for squamous cell esophageal carcinoma.

    by Noriko Kobayashi, Hidetsugu Nakayama, Yoshiaki Osaka, Shingo Tachibana, Sachika Nogi, Yu Tajima, Mitsuru Okubo, Ryuji Mikami, Naoto Kanesaka, Shinji Sugahara, et al.

    Patients with T3 or more squamous cell esophageal cancer underwent low-dose preoperative radiotherapy with chemotherapy, to reduce local recurrence, followed by surgery. The aim was to ascertain tumor response and assess prognostic factors. Between May 2002 and June 2011, 37 consecutive patients with esophageal cancer underwent chemoradiotherapy followed by surgery. The numbers of patients in clinical stages IIA/IIIA/IIIB/IIIC were 2/24/7/4, respectively. All were given a dose of 30 Gy in 15 fractions, with concurrent chemotherapy using cisplatin and fluorouracil. Curative surgery was performed a median of 1.2 months after completion of chemoradiotherapy. Based on the findings from surgery, 26 patients (70%) achieved a stage reduction and six patients (16%) had a complete pathological response. The numbers of patients undergoing resections microscopically complete, with microscopically positive margins, and macroscopically positive margins were 33, 3, and 1, respectively. During a median follow-up period of 22.5 months, the two-year progression-free survival and overall survival were 62.1% [95% confidence interval (CI)=45.8 to 78.4%] and 71.9% [95% CI=55.1 to 88.7%], respectively. Statistically significant prognostic factors for overall survival were age [hazard ratio=6.6; 95% CI=1.1 to 38; p=0.04] and pathological T factor [hazard ratio=10.2; 95% CI=1.4 to 77; p=0.02]. No patients died as a result of surgery. Seventy percent of patients with esophageal cancer who received radiotherapy dose of 30 Gy in 15 fractions combined with chemotherapy achieved a stage reduction with low toxicity.


  • Biopsy for custom-made treatment: mRNA expression level of cancer-critical genes from gastric/colorectal cancer tissues obtained by endoscopic biopsy.

    by Kazuhiko Tamura, Takafumi Watanabe, Masanobu Enomoto, Hideo Sudou, Jiro Ogata, Shigeki Satou, Yoshiaki Kataba, Yoshiaki Osaka, Yuu Takagi, Akihiko Tsuchida, et al.

    33 Background: In this study, we measured the mRNA expression level of cancer-critical genes from the gastric/colorectal cancer tissues obtained through endoscopic biopsy before treatments and compared its consistency with the sample tissues surgically resected from identical cases. Methods: The study was made on 13 gastric and 19 colorectal cancer cases with patients’ consent. We picked identical cases and measured mRNA expression levels from the tissues endoscopically taken before treatment and the surgically resected ones. For the measurement, DNP (DanenbergTumorProfile) method was used. Examination items are as follows: TS, DPD, TP, FPGS, GGH, DHFR, ERCC1, Topo-I, EGFR, and VEGF. Results: Upon comparing the consistency between endoscopically sampled biopsy tissues and surgically taken tissues from identical cases, it was found that eight out of ten items showed strong correlations in colorectal cancer cases. The results are as follows: FPGS(r=0.91, p Conclusions: Today’s progresses of preoperative chemotherapy and radiotherapy and developments of endoscopic and surgical treatments allow diverse options for treatments. In such circumstances, the significance of knowing the expression of cancer-critical genes between individuals before treatment in conducting custom-made treatment is profound. There are two issues in applying the expression of cancer-critical genes found through endoscopic biopsy: one is whether enough cancer cells can be obtained through biopsy, and the other is whether the sampled cancer cells reflect the characteristics of primary focus. While there remain issues to be addressed, certain results were achieved in this study. Currently, we are working on accumulating cases to compare them and find out whether the results can be applied to custom-made treatments.

    • 1 February 2011
      • Vol. 31  (2) , 633-8

    Phase II study of combined chemotherapy with docetaxel, CDDP and 5-FU for highly advanced esophageal cancer.

    by Yoshiaki Osaka, Motoo Shinohara, Sumito Hoshino, Takashi Ogata, Yu Takagi, Akihiko Tsuchida, Tatsuya Aoki

    Advanced esophageal cancer with widespread metastasis to lymph nodes or other organs is difficult to treat and has an extremely poor prognosis. A new combined chemotherapy of docetaxel with cisplatin (CDDP) and 5-fluorouracil (5-FU) (DPF therapy) was performed and its efficacy and safety were examined. Among those hospitalized between May 2003 and October 2009, 30 patients with stage III or stage IV unresectable, untreated advanced esophageal squamous cell carcinoma which had invaded other organs were enrolled in this study. The regimen of DPF therapy was as follows: a set of intravenous drips of 60 mg/m(2) of docetaxel (day 1), 60 mg/m(2) of CDDP (day 1) and 800 mg/m(2) of 5-FU (days 1-5) was administered twice at an interval of 3 to 4 weeks. Antitumor effects, adverse reactions and treatment outcomes were then examined. The patients included 26 men and 4 women aged 40 to 73 years (average age, 58.1 years), and the performance status (PS) was 1 in 18 cases and 2 in 12 cases. The main location of the esophageal cancer was the upper/middle/lower thoracic esophagus in 7/14/9 cases, respectively. Clinical stage was III in 5 cases and IV in 25. The effective rate of DPF therapy was 83.3% for the primary lesion (complete response, CR: 4 cases, partial response, PR: 21 cases), 72.4% for lymph node metastasis (CR: 3 cases, PR: 18 cases) and 72.0% for distant organ metastasis (CR: 3 cases, PR: 15 cases). The observed adverse reactions of grade 2 or higher of National Cancer Institute-Common Toxicity Criteria (NCI-CTC) included anemia (16.7%), leukopenia (73.3%), liver dysfunction (20.0%), anorexia (16.7%), stomatitis (33.3%), esophagitis (16.7%), alopecia (16.7%) and diarrhea (26.7%). The therapy completion rate was 96.7% and the therapy-related death rate was 3.3%. Treatments given after the completion of the DPF therapy were surgery in 6 cases, chemotherapy such as additional DPF in 12, chemoradiation in 4, esophageal stent placement in 1, and no treatment in 7. The patients' median survival time was 271 days, the 1-year survival rate was 41.9% and the 5-year survival rate was 13.3%. DPF therapy can be used as a standard chemotherapy for advanced esophageal cancer in view of its strong antitumor effect and relatively safe outcome.


    • 1 November 2008
      • Vol. 35  (12) , 2042-4

    [A case of stenosis of the reconstructed jejunum due to recurrent cancer after total gastrectomy in which stent-in-stent placement was effective].

    by Yoshihiro Ota, Yu Takagi, Yoshiaki Osaka, Sumito Hoshino, Motoo Shinohara, Hideo Sudo, Akihiko Tsuchida, Tatsuya Aoki

    We report one case of stenosis of the reconstructed jejunum due to recurrent cancer after total gastrectomy in which stenting was effective and good QOL was achieved. The patient was a 70-year-old woman. In July 2000, the patient underwent total gastrectomy.Roux-en Y reconstruction with a diagnosis of gastric cancer. The pathological diagnosis was U-Post, Type 3, por 1, T3, N1, H0, P0, CY0, M0, and Stage IIIA. From 9 months after the operation, aphagia occurred and stenosis of the reconstructed jejunum was noted. Based on a biopsy of the stenosis, a diagnosis of post-operative recurrent gastric cancer was made. Although the patient received two cycles of low-dose FP therapy, complete response was not obtained, and the patient stayed at home under the IVH control for about 4 months. In June 2001, the patient was hospitalized for a stent placement due to the patient's request. After a guide wire was endoscopically inserted and a good passage on the anal side of the stenosis was confirmed, a stent was placed. Self Expandable Metallic Stent (SEMS) was used. Following the stent placement, the patient was able to ingest orally, but 6.5 months later, stenotic symptoms developed and another stent was deployed (stent in stent). Stenting is relatively simple and less invasive, which is useful for the improvement of QOL and in recurrent cases as well.

    • 27 June 2007
      • Vol. 54  (75) , 770-4

    Comparison of the effects on cardiopulmonary function of ultrathin transnasal versus normal diameter transoral esophagogastroduodenoscopy in Japan.

    by Takashi Kawai, Ikuko Miyazaki, Kenji Yagi, Mikinori Kataoka, Kohei Kawakami, Tetsuya Yamagishi, Atsushi Sofuni, Takao Itoi, Fuminori Moriyasu, Yoshiaki Osaka, et al.

    Transnasal esophagogastroduodenoscopy (EGD) is reported to be more pleasant than conventional transoral EGD. In this study, we compared the hemodynamic effects of transnasal and transoral EGD. The subjects were 120 patients with upper gastrointestinal conditions. Transnasal and transoral EGD were performed on 60 subjects each. Oxygen saturation, heart rate and blood pressure were monitored. Subjects were also asked for their condition with each EGD. VAS scores for discomfort at the insertion, and for trouble breathing and nausea during the procedure, were significantly lower for transnasal than for transoral EGD. A significant increase in the heart rate and significant decrease in oxygen saturation were seen only in the transoral group during EGD. The double product (heart rate x systolic blood pressure) was also significantly increased only in the transoral group. No significant changes were seen in the transnasal EGD. Double product has been reported to correlate with myocardial oxygen consumption. Transnasal EGD is a safe technique, and is not only less stressful to patients, but also has fewer hemodynamic effects than the transoral method.


  • Open Access

    The Present Status and an Analysis of Working Conditions of Surgeons. Work Conditions and Cumulative Fatigue of Surgeons.

    by Yasuhisa Koyanagi, Yoshiaki Osaka, Tatsuya Aoki, Hirotoshi Sato

    現代の外科医の勤務状況と疲労の関係,さらには疲労の蓄積と医療事故との関連性を検討するため,大学病院および公的病院に勤務する計324人の外科医に対し,勤務状況と仕事による精神的,身体的疲労に対するアンケート調査を施行した.その結果,蓄積的疲労徴候は1: 大学病院に勤務する研修医やレジデント2: 給与,勤務条件への不満があり,他病院への移動を希望している医師3: 勤務が多忙で体力の限界を感じたことがあると答えた医師においてより顕著であった.またインシデント経験のある医師は精神的,身体的疲労が蓄積している状態であることがわかった. 以上から蓄積的疲労徴候の顕著な外科医は医療事故を起こす可能性が高いことが示唆された.外科医の疲労蓄積を軽減し,医療事故を少なくするためには,診療・勤務体制のさまざまな改革と,外科医個々の仕事や生活に対する意識改革が必要であると思われた.